The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions

Summary

Developing novel anti-platelet therapies is an important clinical strategy for the prevention of arterial thromboses which cause heart attacks and most strokes. Thrombin activates platelets via protease-activated receptors (PARs), and PAR antagonists are currently under investigation as antithrombotics. Yet despite these clinical advances, the importance of PARs to platelet activation during thromboses formed under pathological conditions has not been investigated. To this end, we examined the role of PAR-dependent platelet activation in thrombus formation in the presence of elevated blood shear rates. We used two in vivo thrombosis models and an ex vivo whole blood flow approach in PAR4-/-mice, whose platelets are unresponsive to thrombin, to show that the contribution of PAR-mediated platelet activation to thrombosis is diminished at pathological blood shear rates as a direct result of decreased incorporation of thrombin-activated platelets into growing thrombi. Our ex vivo observations were replicated in human whole blood treated with a PAR1 antagonist. These results define a novel, shear-regulated role for thrombin/PAR-dependent platelet activation during thrombosis and provide important insights into the conditions under which PAR antagonists may best be used for the prevention of acute coronary syndromes.

Keywords

Blood shear - platelets - protease-activated receptors - thrombin - thrombosis

• References

• 1 American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, USA: American Heart Association; 2006
• 2 CARS Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.. Lancet 1997; 350: 389-396.
• 3 Fiore LD, Ezekowitz MD, Brophy MT. et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.. Circulation 2002; 105: 557-563.
• 4 Hurlen M, Abdelnoor M, Smith P. et al. Warfarin, aspirin, or both after myocardial infarction.. N Engl J Med 2002; 347: 969-974.
• 5 Becker RC.. Antithrombotic therapy after myocardial infarction. N Engl J Med 2002; 347: 1019-1022.
• 6 Andreotti F, Testa L, Biondi-Zoccai GG. et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.. Eur Heart J 2006; 27: 519-526.
• 7 Morrow DA, Scirica BM, Fox KA. et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158: 335-341 e3.
• 8 TRACER Committees.. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009; 158: 327-334 e4
• 9 Coughlin SR.. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
• 10 Hamilton JR.. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev 2009; 23: 61-65.
• 11 Sambrano GR, Weiss EJ, Zheng YW. et al. Role of thrombin signalling in platelets in haemostasis and thrombosis.. Nature 2001; 413: 74-78.
• 12 Hamilton JR, Cornelissen I, Coughlin SR.. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.. J Thromb Haemost 2004; 2: 1429-1435.
• 13 Vandendries ER, Hamilton JR, Coughlin SR. et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.. Proc Natl Acad Sci USA 2007; 104: 288-292.
• 14 Camerer E, Duong DN, Hamilton JR. et al. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency.. Blood 2004; 103: 152-154.
• 15 Weiss EJ, Hamilton JR, Lease KE. et al. Protection against thrombosis in mice lacking PAR3.. Blood 2002; 100: 3240-3244.
• 16 Cornelissen I, Palmer D, David T. et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.. Proc Natl Acad Sci USA 2010; 107: 18605-18610.
• 17 Sturgeon SA, Jones C, Angus JA. et al. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals.. J Pharmacol Toxicol Methods 2006; 53: 20-29.
• 18 Maxwell MJ, Yuan Y, Anderson KE. et al. SHIP1 and Lyn Kinase Negatively Regulate Integrin alpha IIb beta 3 signaling in platelets.. J Biol Chem 2004; 279: 32196-32204.
• 19 Torr S, Noble MI, Folts JD.. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin. Cardiovasc Res 1990; 24: 465-470.
• 20 Folts J.. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83 (Suppl. 06) IV3-14.
• 21 Goncalves I, Nesbitt WS, Yuan Y. et al. Importance of temporal flow gradients and integrin alphaIIbbeta3 mechanotransduction for shear activation of platelets.. J Biol Chem 2005; 280: 15430-15437.
• 22 Kulkarni S, Nesbitt WS, Dopheide SM. et al. Techniques to examine platelet adhesive interactions under flow.. Methods Mol Biol 2004; 272: 165-186.
• 23 Ono A, Westein E, Hsiao S. et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth.. Blood 2008; 112: 90-99.
• 24 Inauen W, Baumgartner HR, Bombeli T. et al. Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood. Arteriosclerosis 1990; 10: 607-615.
• 25 Kirchhofer D, Sakariassen KS, Clozel M. et al. Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 1993; 81: 2050-2058.
• 26 Fressinaud E, Sakariassen KS, Rothschild C. et al. Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. Blood 1992; 80: 988-994.
• 27 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
• 28 Goto S, Ogawa H, Takeuchi M. et al. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.. Eur Heart J 2010; 31: 2601-2613.
• 29 Becker RC, Moliterno DJ, Jennings LK. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.. Lancet 2009; 373: 919-928.
• 30 Belval T, Hellums JD, Solis RT.. The kinetics of platelet aggregation induced by fluid-shearing stress. Microvascular Res 1984; 28: 279-288.
• 31 Peterson DM, Stathopoulos NA, Giorgio TD. et al. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987; 69: 625-628.
• 32 Yong AS, Pennings GJ, Chang M. et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel.. Blood 2011; 117: 11-20.
• 33 Nesbitt WS, Westein E, Tovar-Lopez FJ. et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation.. Nat Med 2009; 15: 665-673.
• 34 Berny MA, Munnix IC, Auger JM. et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 5: e10415.